Research Study

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3)
Principal Investigator 
Raewyn Broady

Overview

Body Locations and Systems 
Leukemia
ClinicalTrials.gov# 
NCT03112603
Status 
Recruiting
Study Start/End 
Jan 12, 2018 to Jul 30, 2020
Locations 
Vancouver General Hospital
Name/Title 
Larissa Pals, Research Assistant
Phone 
604-875-4111 ext.22967
Purpose of Study 

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.